Holen Sie sich die Stockscreener-App
21.84
3.39%
-0.86
Schlusskurs vom Vortag:
$22.70
Offen:
$22.71
24-Stunden-Volumen:
332.47K
Relative Volume:
0.23
Marktkapitalisierung:
$2.75B
Einnahmen:
$247.00M
Nettoeinkommen (Verlust:
$-353.00M
KGV:
-6.6176
EPS:
-3.3003
Netto-Cashflow:
$-484.00M
1W Leistung:
-0.81%
1M Leistung:
+15.91%
6M Leistung:
+90.36%
1J Leistung:
+129.87%
1-Tages-Spanne:
$21.69
$23.06
1-Wochen-Bereich:
$21.41
$24.91
52-Wochen-Spanne:
$6.50
$26.40
Arcus Biosciences Inc Stock (RCUS) Company Profile
Firmenname
Arcus Biosciences Inc
Sektor
Branche
Telefon
(510) 694-6200
Adresse
3928 POINT EDEN WAY, HAYWARD, CA
Compare RCUS vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
21.91 | 2.85B | 247.00M | -353.00M | -484.00M | -3.3003 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.70 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
744.82 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
696.88 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.61 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.63 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-12 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2026-01-13 | Hochstufung | Goldman | Neutral → Buy |
| 2026-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-02-26 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | Eingeleitet | H.C. Wainwright | Neutral |
| 2024-10-08 | Eingeleitet | Wells Fargo | Overweight |
| 2022-11-18 | Eingeleitet | BofA Securities | Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2020-11-24 | Eingeleitet | Berenberg | Buy |
| 2020-11-23 | Eingeleitet | Evercore ISI | Outperform |
| 2020-04-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-09-27 | Eingeleitet | Mizuho | Buy |
| 2019-05-24 | Fortgesetzt | Citigroup | Buy |
| 2018-10-09 | Eingeleitet | Wedbush | Outperform |
| 2018-04-09 | Eingeleitet | Citigroup | Buy |
| 2018-04-09 | Eingeleitet | Goldman | Neutral |
| 2018-04-09 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Arcus Biosciences Inc Aktie (RCUS) Neueste Nachrichten
WINTON GROUP Ltd Purchases Shares of 92,229 Arcus Biosciences, Inc. $RCUS - MarketBeat
Why Arcus Biosciences (RCUS) Is Up 9.5% After New Casdatifan Data And Pipeline Expansion - simplywall.st
Arcus Biosciences (RCUS) Valuation After Casdatifan Kidney Cancer Data Pipeline Update And Earnings - Sahm
How (RCUS) Movements Inform Risk Allocation Models - Stock Traders Daily
New Arcus Biosciences hires receive stock options at $23.43 - Stock Titan
Arcus Biosciences at Leerink Conference: Casdatifan’s Promising Data By Investing.com - Investing.com Canada
RCUS News Today | Why did Arcus Biosciences stock go down today? - MarketBeat
Is Arcus Biosciences Inc still a buy after recent gainsWeekly Trading Summary & Comprehensive Market Scan Insights - baoquankhu1.vn
Performance Recap: Can Arcus Biosciences Inc disrupt its industryJuly 2025 Macro Moves & Scalable Portfolio Growth Methods - baoquankhu1.vn
Vanguard Group Inc. Increases Stock Holdings in Arcus Biosciences, Inc. $RCUS - MarketBeat
Here’s what analysts think about Arcus Biosciences (RCUS) - MSN
Aug Sectors: Is Arcus Biosciences Inc in a long term uptrendQuarterly Performance Summary & Free High Return Stock Watch Alerts - baoquankhu1.vn
Citigroup Raises Arcus Biosciences (RCUS) Price Target to $45 | - GuruFocus
Citigroup Raises Arcus Biosciences (NYSE:RCUS) Price Target to $45.00 - MarketBeat
Fisher Asset Management LLC Acquires 640,990 Shares of Arcus Biosciences, Inc. $RCUS - MarketBeat
RCUS SEC FilingsArcus Bioscience 10-K, 10-Q, 8-K Forms - Stock Titan
Arcus (RCUS) Q4 2025 Earnings Call Transcript - AOL.com
RCUS Stock Jumps 17.5% Despite $353M Net Loss: What $34 Fair Value Signals - TIKR.com
Arcus Biosciences (RCUS) Is Up 27.0% After Casdatifan Kidney Cancer Data And TKI-Free Strategy Shift - simplywall.st
The Analyst Verdict: Arcus Biosciences In The Eyes Of 5 Experts - Sahm
Arcus Biosciences: Q4 Beat And Casdatifan’s Story So Far (NYSE:RCUS) - Seeking Alpha
RCUS Analyst Rating Updated by Leerink Partners | RCUS Stock New - GuruFocus
Arcus Biosciences (NYSE:RCUS) Stock Price Expected to Rise, Leerink Partners Analyst Says - MarketBeat
Arcus Biosciences (NYSE:RCUS) Shares Up 9.5%Here's What Happened - MarketBeat
Arcus Biosciences (NYSE:RCUS) Given "Buy" Rating at HC Wainwright - MarketBeat
Arcus Biosciences Puts Casdatifan Kidney Cancer Data At Center Stage - Yahoo Finance
Arcus Biosciences (RCUS) Analyst Rating Reaffirmed with Target P - GuruFocus
HC Wainwright Brokers Increase Earnings Estimates for RCUS - MarketBeat
Performance Recap: Is Arcus Biosciences Inc stock a buy or sellEarnings Miss & Community Consensus Trade Alerts - baoquankhu1.vn
Can Arcus Biosciences Inc stock double in the next year2025 Growth vs Value & Accurate Technical Buy Alerts - baoquankhu1.vn
Assessing Arcus Biosciences (RCUS) Valuation After Recent Share Price Rebound And Casdatifan Expectations - simplywall.st
Arcus Biosciences Q4 Earnings Call Highlights - Yahoo Finance
Arcus Biosciences (RCUS) Posts US$106 Million Q4 Loss Reinforcing Bearish Profitability Narratives - Sahm
Arcus Biosciences, Inc. 2025 Q4ResultsEarnings Call Presentation (NYSE:RCUS) 2026-02-27 - Seeking Alpha
Arcus Biosciences (RCUS) Stock Analysis: Is A 65% Upside In Reach? - DirectorsTalk Interviews
MRGPRX2 antagonists disclosed in Arcus Biosciences patent - BioWorld MedTech
FY2030 Earnings Estimate for RCUS Issued By HC Wainwright - MarketBeat
Cancer and immune drug developer Arcus Biosciences offers March webcast - Stock Titan
Is Arcus Biosciences (RCUS) Pricing Reflect Its 1‑Year Surge And Mixed Valuation Signals - simplywall.st
Arcus Biosciences, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Arcus Biosciences earnings beat by $0.21, revenue fell short of estimates - Investing.com Canada
Arcus Biosciences Inc (RCUS) Q4 2025 Earnings Call Highlights: S - GuruFocus
Decoding Arcus Biosciences Inc (RCUS): A Strategic SWOT Insight - GuruFocus
Arcus Biosciences Q4 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Arcus Biosciences beats EPS expectations in Q4 2025 - Investing.com Nigeria
RCUS: Casdatifan delivers superior efficacy in RCC, driving strong financials and market potential - TradingView
Arcus Biosciences Files For Mixed Shelf - TradingView
Arcus Biosciences (NYSE:RCUS) Issues Quarterly Earnings Results - MarketBeat
Arcus Biosciences : Reports Fourth-Quarter and Full-Year 2025 Financial Results an... - marketscreener.com
RCUS: 2025 net loss widened to $353M on $247M revenue; $1.0B cash supports late-stage pipeline - TradingView
Earnings Flash (RCUS) Arcus Biosciences, Inc. Reports Q4 Revenue $33.0M, vs. FactSet Est of $35.7M - marketscreener.com
Finanzdaten der Arcus Biosciences Inc-Aktie (RCUS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):